August 5, 2011 -- Zhejiang Hisun Pharmaceutical will spend $2 million to buy a 25% stake in PharmTak Inc, a US CRO that specializes in formulations. Based in San Jose, CA, PharmTak develops new delivery systems of drugs offering controlled/extended release, quick release/nano particles, topical/transdermal application, and solid implants. Its services extend from pre-clinical through all stages of clinical development. More details....
Stock Symbol: (SHA: 600267)
